Search results for "DISCOVERY"

showing 10 items of 4119 documents

Suitability of MMGBSA for the selection of correct ligand binding modes from docking results

2019

The estimation of the correct binding mode and affinity of a ligand into a target protein using computational methods is challenging. However, docking can introduce poses from which the correct binding mode could be identified using other methods. Here, we analyzed the reliability of binding energy estimation using the molecular mechanics‐generalized Born surface area (MMGBSA) method without and with energy minimization to identify the likely ligand binding modes within docking results. MMGBSA workflow (a) outperformed docking in recognizing the correct binding modes of androgen receptor ligands and (b) improved the correlation coefficient of computational and experimental results of rescor…

molecular modelingstructure based drug-designreceptor and ligandsproteiinitliganditlaskennallinen kemiadrug discoverylääkesuunnittelu
researchProduct

Reuse of Food Waste: The Chemical Composition and Health Properties of Pomelo (Citrus maxima) Cultivar Essential Oils

2022

The aim of the present study is to investigate the chemical profile, antioxidant activity, carbohydrate-hydrolysing enzyme inhibition, and hypolipidemic effect of essential oils (EOs) extracted from Sicilian Citrus maxima (pomelo) flavedo. Using gas-chromatography-mass spectrometry analysis (GC-MS) we analysed the Eos of five cultivars of C. maxima, namely, ‘Chadock’, ‘Maxima’, ‘Pyriformis’, ‘Terracciani’, and ‘Todarii’, and their blends. The antioxidant activity was performed by using a multi-target approach using 2,2′-Azino-Bis-3-Ethylbenzothiazoline-6-Sulfonic acid (ABTS), 2,2-Diphenyl-1-picrylhydrazyl (DPPH), ferric reduc…

monoterpene hydrocarbonscarbohydrate-hydrolysing enzymesOrganic ChemistryPharmaceutical SciencePCA and HCA analyses‘recirculate’gas chromatography-mass spectrometryAnalytical ChemistryCitrus maxima (Burm.) Merr<i>Citrus maxima</i> (Burm.) Merr.; gas chromatography-mass spectrometry; monoterpene hydrocarbons; ‘recirculate’; PCA and HCA analyses; carbohydrate-hydrolysing enzymes; lipaseChemistry (miscellaneous)Drug DiscoverylipaseMolecular MedicinePhysical and Theoretical Chemistry
researchProduct

RNA-mediated therapies in myotonic dystrophy

2018

Myotonic dystrophy 1 (DM1) is a multisystemic neuromuscular disease caused by a dominantly inherited 'CTG' repeat expansion in the gene encoding DM Protein Kinase (DMPK). The repeats are transcribed into mRNA, which forms hairpins and binds with high affinity to the Muscleblind-like (MBNL) family of proteins, sequestering them from their normal function. The loss of function of MBNL proteins causes numerous downstream effects, primarily the appearance of nuclear foci, mis-splicing, and ultimately myotonia and other clinical symptoms. Antisense and other RNA-mediated technologies have been applied to target toxic-repeat mRNA transcripts to restore MBNL protein function in DM1 models, such as…

musculoskeletal diseases0301 basic medicinePharmacologycongenital hereditary and neonatal diseases and abnormalitiesMessenger RNAMyotonin-protein kinaseRNABiologymedicine.diseaseMyotoniaMyotonic dystrophyMyotonin-Protein KinaseCell biology03 medical and health sciences030104 developmental biologyDrug DiscoverymedicineAnimalsHumansMyotonic DystrophyRNARNA MessengerTrinucleotide repeat expansionGeneLoss functionDrug Discovery Today
researchProduct

&lt;p&gt;Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model&lt;/p&gt;

2019

Background After a trauma, exuberant tissue healing with fibrosis of the joint capsule can lead to posttraumatic joint stiffness (PTJS). Losartan and atorvastatin have both shown their antifibrotic effects in different organ systems. Objective The purpose of this study was the evaluation of the influence of losartan and atorvastatin on the early development of joint contracture. In addition to joint angles, the change in myofibroblast numbers and the distribution of bone sialoprotein (BSP) were assessed. Study design and methods In this randomized and blinded experimental study with 24 rats, losartan and atorvastatin were compared to a placebo. After an initial joint injury, rat knees were …

musculoskeletal diseases0301 basic medicinePharmacologymedicine.medical_specialtyArticular capsule of the knee jointbusiness.industryAtorvastatinUrologyPharmaceutical SciencePlacebo03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureLosartan030220 oncology & carcinogenesisJoint stiffnessDrug DiscoveryJoint capsulemedicineJoint Contracturemedicine.symptomContracturebusinessmedicine.drugDrug Design, Development and Therapy
researchProduct

Myotonic dystrophy: candidate small molecule therapeutics

2017

Myotonic dystrophy type 1 (DM1) is a rare multisystemic neuromuscular disorder caused by expansion of CTG trinucleotide repeats in the noncoding region of the DMPK gene. Mutant DMPK transcripts are toxic and alter gene expression at several levels. Chiefly, the secondary structure formed by CUGs has a strong propensity to capture and retain proteins, like those of the muscleblind-like (MBNL) family. Sequestered MBNL proteins cannot then fulfill their normal functions. Many therapeutic approaches have been explored to reverse these pathological consequences. Here, we review the myriad of small molecules that have been proposed for DM1, including examples obtained from computational rational …

musculoskeletal diseases0301 basic medicineTherapeutic gene modulationcongenital hereditary and neonatal diseases and abnormalitiesMutantComputational biologyBiologyMyotonic dystrophyMyotonin-Protein Kinase03 medical and health sciences0302 clinical medicineTrinucleotide RepeatsDrug DiscoveryGene expressionmedicineAnimalsHumansMyotonic DystrophyGenePharmacologyRegulation of gene expressionGeneticsDrug RepositioningRational designmedicine.diseaseSmall moleculeHigh-Throughput Screening Assays030104 developmental biologyGene Expression RegulationDrug Design030217 neurology & neurosurgeryDrug Discovery Today
researchProduct

miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy

2019

International audience; Unstable CTG expansions in the 3' UTR of the DMPK gene are responsible for myotonic dystrophy type 1 (DM1) condition. Muscle dysfunction is one of the main contributors to DM1 mortality and morbidity. Pathways by which mutant DMPK trigger muscle defects, however, are not fully understood. We previously reported that miR-7 was downregulated in a DM1 Drosophila model and in biopsies from patients. Here, using DM1 and normal muscle cells, we investigated whether miR-7 contributes to the muscle phenotype by studying the consequences of replenishing or blocking miR-7, respectively. Restoration of miR-7 with agomiR-7 was sufficient to rescue DM1 myoblast fusion defects and…

musculoskeletal diseases0301 basic medicineoligonucleotidemuscle atrophyautophagyBiologyMyotonic dystrophyArticleMuscleblind03 medical and health scienceschemistry.chemical_compoundMyoblast fusion0302 clinical medicineDrug DiscoverymicroRNAmedicineMBNL1MyocyteMyotonic DystrophymiRNAtherapy[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAutophagyUPS systemmiR-7medicine.diseasePhenotypeMuscle atrophyCell biology030104 developmental biologychemistry030220 oncology & carcinogenesisMolecular MedicineCTG expansionsmedicine.symptom[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Interaction of allopurinol with phenprocoumon in man.

1977

Conditions in two patients on long-term phenprocoumon (Marcumar®) treatment are reported who had signs of phenprocoumon overdosage when given simultaneously allopurinol. The determination of phenprocoumon plasma concentrations in one patient showed that phenprocoumon accumulates for several weeks during treatment with allopurinol. Signs of phenprocoumon overdosage thus can appear long time after starting allopurinol treatment.

musculoskeletal diseasesAdultMalecongenital hereditary and neonatal diseases and abnormalitiesAllopurinolMyocardial InfarctionAllopurinolPharmacologyPhenprocoumonDrug DiscoveryMedicineHumansDrug InteractionsBlood CoagulationGenetics (clinical)integumentary systembusiness.industrynutritional and metabolic diseasesGeneral Medicine4-HydroxycoumarinsDrug interactionMiddle AgedPlasma concentrationPhenprocoumonMolecular MedicineBlood Coagulation TestsbusinessMathematicsmedicine.drugKlinische Wochenschrift
researchProduct

Hypokalemic rhabdomyolysis associated with Bartter's syndrome.

1983

Severe potassium deficiency is an uncommon cause of rhabdomyolysis. We recently treated a 45-year-old patient with myalgia, serious generalized weakness, increased serum creatine kinase and myoglobin level as well as excessive hypokalemia. Histological examination of deltoid muscle biopsy showed rhabdomyolysis. After complete recovery of muscle damage by potassium substitution Bartter's syndrome proved to be the cause of initial and persistent hypokalemia.

myalgiaMalemedicine.medical_specialtyendocrine system diseasesHypokalemiaurologic and male genital diseasesGastroenterologyNecrosisInternal medicineDeltoid muscleDrug DiscoveryBiopsyHyperaldosteronismmedicineHumansCreatine KinaseGenetics (clinical)Histological examinationmedicine.diagnostic_testbusiness.industryMyoglobinMusclesMyoglobinuriaBartter SyndromeGeneral MedicineMiddle Agedmedicine.diseaseHypokalemiaBartter's syndromeAnesthesiaPotassiumMolecular MedicinePotassium deficiencymedicine.symptombusinessRhabdomyolysisKlinische Wochenschrift
researchProduct

Myoadenylate deaminase deficiency

1987

Myoadenylate deaminase (MAD) is the rate-limiting enzyme in the purine nucleotide cycle which is biochemically linked to glycolysis and the citric cycle and thereby providing energy during intense muscular activity. In muscle fibers, myoadenylate deaminase operates at considerably higher activity levels than in other organs. First detected using enzyme-histochemical methods, it now appears that deficiency of myoadenylate deaminase is one of the most frequent enzyme defects in muscle. The primary defect may occur as an isolated nosological entity or not infrequently it is also associated with a large spectrum of different neuromuscular conditions. It seems to be the primary unassociated MAD …

myalgiaWeaknessmedicine.medical_specialtyBiopsyElectromyographyMetabolic myopathyBiologyGastroenterologyAMP Deaminase03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryBiopsymedicineHumansGenetics (clinical)030304 developmental biology0303 health sciencesmedicine.diagnostic_testMusclesMuscle weaknessAMP deaminaseNeuromuscular DiseasesGeneral Medicinemedicine.diseaseEndocrinologyNucleotide DeaminasesMolecular MedicineSarcoidosismedicine.symptom030217 neurology & neurosurgeryKlinische Wochenschrift
researchProduct

Ferritin-Coated SPIONs as New Cancer Cell Targeted Magnetic Nanocarrier

2023

Superparamagnetic iron oxide nanoparticles (SPIONs) may act as an excellent theragnostic tool if properly coated and stabilized in a biological environment, even more, if they have targeting properties towards a specific cellular target. Humanized Archaeoglobus fulgidus Ferritin (HumAfFt) is an engineered ferritin characterized by the peculiar salt-triggered assembly-disassembly of the hyperthermophile Archaeoglobus fulgidus ferritin and is successfully endowed with the human H homopolymer recognition sequence by the transferrin receptor (TfR1 or CD71), overexpressed in many cancer cells in response to the increased demand of iron. For this reason, HumAfFt was successfully used in this stud…

nanoparticleferritinOrganic ChemistrySPIONcoatingPharmaceutical ScienceSPIONs; cancer cell targeting; coating; ferritin; nanoparticlesAnalytical Chemistrycancer cell targetingSPIONsChemistry (miscellaneous)Drug DiscoveryMolecular MedicinenanoparticlesPhysical and Theoretical ChemistryMolecules
researchProduct